Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$563K Buy
4,378
+200
+5% +$23.4K 0.12% 100
2026
Q1
$503K Hold
4,178
0.12% 90
2025
Q4
$440K Sell
4,178
-50
-1% -$4.69K 0.1% 102
2025
Q3
$355K Hold
4,228
0.08% 115
2025
Q2
$335K Hold
4,228
0.09% 113
2025
Q1
$380K Sell
4,228
-68
-2% -$6.35K 0.11% 95
2024
Q4
$427K Hold
4,296
0.12% 93
2024
Q3
$488K Sell
4,296
-57
-1% -$6.77K 0.14% 95
2024
Q2
$539K Sell
4,353
-51
-1% -$6.57K 0.16% 89
2024
Q1
$581K Sell
4,404
-7,630
-63% -$940K 0.16% 74
2023
Q4
$1.31M Buy
12,034
+7,630
+173% +$792K 0.45% 27
2023
Q3
$453K Sell
4,404
-87
-2% -$9.38K 0.16% 65
2023
Q2
$518K Sell
4,491
-50
-1% -$5.68K 0.18% 59
2023
Q1
$483K Sell
4,541
-193
-4% -$20.8K 0.19% 55
2022
Q4
$525K Buy
+4,734
New +$484K 0.23% 44

Other funds holding MRK

Park Edge Advisors's MRK Position: Q2 2026 in Review

Park Edge Advisors increased its Merck (MRK) stake by 4.8% in Q2 2026, buying an estimated $23.4K and bringing the position to 4,378 shares worth $563K. The position accounts for 0.12% of the portfolio, ranked #100.

Park Edge Advisors first reported a position in MRK in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.31M in Q4 2023. 711 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Park Edge Advisors held 4,378 shares of Merck worth $563K as of Q2 2026.
  • Park Edge Advisors bought 200 Merck shares in Q2 2026, an estimated $23.4K.
  • Merck made up 0.12% of Park Edge Advisors's portfolio in Q2 2026, its #100 holding.
  • Park Edge Advisors first reported a position in Merck in Q4 2022 and has held it in 15 quarters since.
  • Park Edge Advisors's Merck position peaked at $1.31M in Q4 2023.
  • 711 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Park Edge Advisors's 13F filing for Q2 2026, filed 13 Jul 2026.